psalexa
logo

Migraine Therapeutics Pipeline Analysis

Migraine Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11245
Available Format:

Migraine is a type of a severe headache that is characterized by the intense throbbing in one area of the head. According to National Institute of Neurological Disorders and Stroke, migraine is three times common in women than in men and it is heralded by visual disturbances such as zig-zag lines vision and flashing lights. People having migraine generally have frequent attacks that cause, anxiety, stress, hormonal level changes, and lack of sleep. The duration of migraine pain ranges from four hours to three days. In some cases, people become extremely sensitive to light and sound. There are two treatment approaches established, relieving the symptoms and preventing the attacks. Allodynic Therapeutics, LLC is in the process of developing ALLOD-2 as pro-inflammatory cytokines release inhibitors for the treatment of migraine. Allergan plc is in the process of developing AGN 241689 as a calcitonin gene-related peptide antagonist for the treatment of migraine. Some of the companies having the pipeline of migraine include Amgen plc, Eli Lilly and Company, Alder Biopharmaceuticals, Inc., and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry